Seeking AlphaWed, 13 May 2026 23:30:45 GMTTravere Therapeutics, Inc. (TVTX) Presents at Bank of America Global Healthcare Conference 2026 TranscriptTVTX-3.42%
BenzingaTue, 05 May 2026 18:41:08 GMTTravere Therapeutics Analysts Increase Their Forecasts Following Q1 EarningsTVTX-3.42%
Seeking AlphaTue, 05 May 2026 11:21:15 GMTTravere Therapeutics, Inc. (TVTX) Q1 2026 Earnings Call TranscriptTVTX-3.42%
Zacks Investment ResearchMon, 04 May 2026 23:01:13 GMTCompared to Estimates, Travere (TVTX) Q1 Earnings: A Look at Key MetricsTVTX-3.42%
Zacks Investment ResearchMon, 04 May 2026 22:10:20 GMTTravere Therapeutics (TVTX) Reports Q1 Loss, Misses Revenue EstimatesTVTX-3.42%
Zacks Investment ResearchTue, 28 Apr 2026 10:56:10 GMTXOMA Royalty (XOMA) Moves 10.7% Higher: Will This Strength Last?TVTX-3.42%
Seeking AlphaTue, 21 Apr 2026 19:40:43 GMTTravere Therapeutics: Still Undervalued Post FSGS ApprovalTVTX-3.42%
The Motley FoolMon, 20 Apr 2026 19:00:37 GMTTravere Therapeutics Director Trims Stake Amid 168% Run, But Is FILSPARI's Revenue Story Just Getting Started?TVTX-3.42%
Investors Business DailyFri, 17 Apr 2026 16:16:04 GMTFour Biotech Stocks Near Buy Points As Earnings Season Kicks InTVTX-3.42%
Seeking AlphaWed, 15 Apr 2026 19:21:56 GMTTravere Therapeutics: Re-Rating Potential As Filspari Wins Full ApprovalTVTX-3.42%
Zacks Investment ResearchWed, 15 Apr 2026 15:41:14 GMTTVTX Stock Soars on FDA Nod for Filspari in Second Kidney IndicationTVTX-3.42%
Zacks Investment ResearchWed, 15 Apr 2026 11:20:35 GMTTravere (TVTX) Soars 37.2%: Is Further Upside Left in the Stock?TVTX-3.42%
BenzingaTue, 14 Apr 2026 13:55:56 GMTFDA Approval For Travere's Drug Expands Reach To Broader Rare Kidney Disease PatientsTVTX-3.42%
Investors Business DailyTue, 14 Apr 2026 13:02:39 GMTTravere Therapeutics Stock Skyrockets On FDA ApprovalTVTX-3.42%
Seeking AlphaTue, 14 Apr 2026 02:41:44 GMTTravere Therapeutics, Inc. (TVTX) Discusses FDA Approval of FILSPARI as First Approved Medicine for FSGS TranscriptTVTX-3.42%
Seeking AlphaTue, 24 Feb 2026 12:39:02 GMTTravere Therapeutics: FILSPARI Drives Revenue, FSGS PDUFA LoomsTVTX-3.42%
Seeking AlphaFri, 20 Feb 2026 01:15:06 GMTTravere Therapeutics, Inc. (TVTX) Q4 2025 Earnings Call TranscriptTVTX-3.42%
Zacks Investment ResearchThu, 19 Feb 2026 23:31:18 GMTTravere (TVTX) Reports Q4 Earnings: What Key Metrics Have to SayTVTX-3.42%
Zacks Investment ResearchThu, 19 Feb 2026 23:10:17 GMTTravere Therapeutics (TVTX) Matches Q4 Earnings EstimatesTVTX-3.42%
